Longevity Vision Fund comes out of stealth during the Longevity Leaders forum in London
Credit: Insilico Medicine
Monday, February 4th, London, UK – Recent breakthroughs in diagnostics and therapeutics of age-related diseases and aging itself lead to the emergence of the longevity biotechnology industry with a number of credible companies and exponential business models. To accelerate this emerging trend a team of professional investors and biotechnology entrepreneurs created the Longevity Vision Fund, a new venture capital fund focused on early-stage technologies and life-science businesses. The Fund seeks to invest in companies that provide products, services, and technologies aimed to extend the period of healthy human life.
“The Fund’s mission is to lead the breakthrough in human longevity and to extend human lifespan worldwide allowing people to live longer, healthier lives”, – said Sergey Young, the Founder of Longevity Vision Fund.
Sergey Young is a visionary and investor with 20 years of experience in the field of human longevity and venture capital investing. Sergey is also development sponsor of Longevity XPRIZE and Innovation Board member at XPRIZE Foundation. Sergey is a Longevity Partner of Bold Capital Partners, and early-stage venture fund partnered with Singularity University and Peter Diamandis. Longevity Vision Fund team will be advised by leading life science experts and prominent venture investors.
The Fund’s goal is to support companies worldwide focused on translating groundbreaking innovation into the next generation of therapeutics increasing human longevity as well as complementary IT products, services, and infrastructure to accelerate innovation in life sciences.
The Fund is Delaware based and has a size of $100m. The Fund cooperates with Bold Capital Partners – the investment vehicle of Peter H. Diamandis.
Adding 20 to 30 healthy years on a person’s life is likely to be the largest market opportunity on Earth. The convergence of Genome Sequencing, AI & Cellular Medicine will enable breakthroughs that will make 100 years old the new 60. I’m proud through our Bold Capital partnership to support Sergey Young and the Longevity Vision Fund”, – said Dr. Peter H. Diamandis.
###
About Longevity Vision Fund:
Longevity Vision Fund, a new venture capital fund focused on early-stage technologies and life-science businesses. The Fund seeks to invest in companies that provide products, services, and technologies aimed to extend the period of healthy human life.
Contacts
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
Media Contact
Qingsong Zhu
[email protected]
240-641-6266
